Stockscreener 앱 받기
14.81
0.47%
0.07
Biohaven Ltd 주식(BHVN)의 최신 뉴스
How To Trade (BHVN) - news.stocktradersdaily.com
Morgan Stanley maintains Biohaven stock with $63 target - Investing.com Australia
Biohaven stock hits 52-week low at $14.36 amid market challenges - Investing.com Australia
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target - Investing.com Australia
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target By Investing.com - Investing.com India
Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments - TipRanks
Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements - TipRanks
Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Cowen reiterates Buy on Biohaven stock, maintains $75 target By Investing.com - Investing.com India
Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - marketscreener.com
Biohaven initiates global Phase 2/3 study of BHV-8000 - TipRanks
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus
TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - PR Newswire
Biohaven’s BHV-1510 shows promise in early cancer trial By Investing.com - Investing.com South Africa
Biohaven’s BHV-1400 shows promise in IgA nephropathy treatment By Investing.com - Investing.com South Africa
Optimistic Buy Rating for Biohaven Ltd. Amid Promising Pipeline and Regulatory Challenges - TipRanks
Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating - TipRanks
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class - The Malaysian Reserve
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors - The Malaysian Reserve
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Trea - StreetInsider
Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - Insider Monkey
Biohaven’s BHV-1400 shows promise in IgA nephropathy treatment - Investing.com Australia
Biohaven (BHVN) Advances Innovative Drug Trials for Immune Diseases | BHVN Stock News - GuruFocus
Biohaven (BHVN) Reports Promising Phase 1 Results for Cancer Tre - GuruFocus
Biohaven Pharma (BHVN) Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day - StreetInsider
Biohaven says anti-cancer agent cut tumor size with Regeneron’s Libtayo in Phase 1 trial - Seeking Alpha
Lost Money on Biohaven Ltd. (BHVN)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Biohaven Ltd. Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and Fgfr3 Antibody Drug Conjugates Incorporating Novel Topoix Payload with Potential to Treat A Wide Variety of Tumors - marketscreener.com
Biohaven’s BHV-1510 shows promise in early cancer trial - Investing.com Australia
Biohaven (BHVN) Reports Promising Early Results in Oncology Prog - GuruFocus
Biohaven Presents Oncology Program Updates And Preliminary Clinical Data - marketscreener.com
Biohaven Pharma (BHVN) Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates - StreetInsider
Breakthrough: Biohaven's New Cancer Drug Achieves Perfect Response Rate in First 6 Patients Treated - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd.BHVN - Longview News-Journal
Inozyme Pharma and Biohaven Pharmaceuticals Announce Leadership Changes Amid Industry Restructuring - geneonline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - GlobeNewswire Inc.
(BHVN) Long Term Investment Analysis - news.stocktradersdaily.com
Biohaven’s SWOT analysis: stock faces regulatory hurdles amid pipeline potential - Investing.com Nigeria
Biohaven (NYSE:BHVN) Downgraded by Royal Bank of Canada to Sector Perform - Defense World
Biohaven (BHVN) Sees Downgraded Rating and Lowered Price Target - GuruFocus
RBC Downgrades Biohaven Amid Market Valuation Concerns - Finimize
Biohaven Has Lots Of Shots, Too Many Risks, RBC Says - marketscreener.com
Biohaven (BHVN) Downgraded by RBC Capital with Price Target Cut | BHVN Stock News - GuruFocus
Biohaven (BHVN) Receives Downgrade Amid Regulatory Concerns | BH - GuruFocus
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $21 From $54, Keeps Speculative Risk - marketscreener.com
RBC downgrades Biohaven to Sector Perform on regulatory risk - TipRanks
41,762 Shares in Biohaven Ltd. (NYSE:BHVN) Purchased by BNP Paribas Financial Markets - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. ... - Eagle-Tribune
In Brief: US FDA Delay Sends Biohaven Shares Down - insights.citeline.com
Healthcare Shake-Up: UnitedHealth And Biohaven Face Setbacks - Finimize
Biohaven (BHVN) Shares Dip as FDA Extends Drug Review Timeline - GuruFocus
Royal Bank of Canada Cuts Biohaven (NYSE:BHVN) Price Target to $54.00 - Defense World
Biohaven (NYSE:BHVN) Upgraded at Cantor Fitzgerald - Defense World
1.89%
3.74%
자본화:
|
볼륨(24시간):